Halozyme Therapeutics, Inc. HALO
NASDAQ · United States · Health Technology
$108.34-2.06 (-1.87%)
Market open· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
| Quarter | Report date | Actual EPS | Estimated EPS | EPS surprise | Actual revenue | Revenue surprise | Price reaction |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 2026-08-06 | 2.28 | 1.79 | +27.6% | $481.00M | +19.6% | +23.4%$83.59→$103.12 |
| Q1 2026 | 2026-05-11 | 1.60 | 1.52 | +5.3% | — | — | +10.6%$64.12→$70.93 |
| Q4 2025 | 2026-02-17 | -0.24 | 2.20 | -110.9% | — | — | -7.8%$79.44→$73.23 |
| Q3 2025 | 2025-11-03 | 1.72 | 1.63 | +5.5% | — | — | +4.4%$65.19→$68.05 |
| Q2 2025 | 2025-08-05 | 1.54 | 1.27 | +21.3% | — | — | — |
| Q1 2025 | 2025-05-06 | 1.11 | 0.95 | +16.8% | — | — | — |
| Q4 2024 | 2025-02-18 | 1.26 | 1.16 | +8.6% | — | — | — |
| Q3 2024 | 2024-10-31 | 1.27 | 1.00 | +27.0% | — | — | — |
The price reaction is the change from the last close before the announcement date to the first close after it - the report may land before the open, during the session or after the close, so this window covers all three. Not investment advice.